Catalyst Pharmaceuticals Reaffirms Guidance
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals (CPRX) reaffirms its full-year 2023 financial guidance, forecasting total revenues between $375 million and $385 million, representing a 75%-80% increase compared to 2022. FIRDAPSE net product revenues are expected to be between $245 million and $255 million, while FYCOMPA net product revenues are forecasted at approximately $130 million.
June 01, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals reaffirms its 2023 financial guidance, projecting a significant increase in total revenues and growth in FIRDAPSE and FYCOMPA net product revenues.
Catalyst Pharmaceuticals' reaffirmed financial guidance for 2023 indicates strong revenue growth and increased net product revenues for FIRDAPSE and FYCOMPA. This positive outlook is likely to have a short-term positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100